AWA
AVXL icon

Aaron Wealth Advisors’s Anavex Life Sciences AVXL Stock Holding History

Aaron Wealth Advisors’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,748
Closed -$21.5K – 249
2022
Q1 		$21.5K Buy
+1,748
New +$21.5K 0.01% 633

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $755M AUM 94.38% 1-Year Est. Return

Aaron Wealth Advisors's AVXL Position: Q2 2022 in Review

Aaron Wealth Advisors sold out of Anavex Life Sciences (AVXL) in Q2 2022, closing a stake of 1,748 shares — an estimated $21.5K sold.

Aaron Wealth Advisors first reported a position in AVXL in Q1 2022 and held it in 1 quarter. The position peaked at $21.5K in Q1 2022. 150 funds tracked by Wall St. Rank hold AVXL as of Q2 2022.

  • Aaron Wealth Advisors reported no remaining Anavex Life Sciences position as of Q2 2022 after selling out during the quarter.
  • Aaron Wealth Advisors sold 1,748 Anavex Life Sciences shares in Q2 2022, an estimated $21.5K.
  • Aaron Wealth Advisors first reported a position in Anavex Life Sciences in Q1 2022 and held it in 1 quarter.
  • Aaron Wealth Advisors's Anavex Life Sciences position peaked at $21.5K in Q1 2022.
  • 150 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2022.

Based on Aaron Wealth Advisors's 13F filing for Q2 2022, filed 22 Jul 2022.